Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A. Bone HG, et al. Among authors: mcclung mr. Osteoporos Int. 2015 Nov;26(11):2721. doi: 10.1007/s00198-015-3274-z. Osteoporos Int. 2015. PMID: 26359183 Free PMC article. No abstract available.
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ. Schnitzer T, et al. Aging (Milano). 2000 Feb;12(1):1-12. Aging (Milano). 2000. PMID: 10746426 Clinical Trial.
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME. Greenspan SL, et al. Among authors: mcclung mr. Ann Intern Med. 2002 May 21;136(10):742-6. doi: 10.7326/0003-4819-136-10-200205210-00009. Ann Intern Med. 2002. PMID: 12020142 Clinical Trial.
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators. Miller PD, et al. J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5. J Clin Endocrinol Metab. 2008. PMID: 18682511 Free PMC article. Clinical Trial.
Validation of the IOF quality of life questionnaire for patients with wrist fracture.
Lips P, Jameson K, Bianchi ML, Goemaere S, Boonen S, Reeve J, Stepan J, Johnell O, van Schoor NM, Dennison E, Kanis JA, Cooper C; Working Group for Quality of Life of the International Osteoporosis Foundation. Lips P, et al. Osteoporos Int. 2010 Jan;21(1):61-70. doi: 10.1007/s00198-009-0946-6. Epub 2009 Jun 6. Osteoporos Int. 2010. PMID: 19504036 Free PMC article.
271 results